Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inecalcitol - Hybrigenics

Drug Profile

Inecalcitol - Hybrigenics

Alternative Names: TX-522

Latest Information Update: 08 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ghent University; Katholieke Universiteit Leuven
  • Developer Hybrigenics
  • Class Alkynes; Antipsoriatics; Secosteroids; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Prostate cancer; Psoriasis

Most Recent Events

  • 23 Oct 2018 Hybrigenics terminates a phase II trial in Psoriasis in France
  • 23 Oct 2018 Discontinued - Phase-I for Prostate cancer in France (PO)
  • 23 Oct 2018 Discontinued - Phase-II for Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA, France, Belgium, Germany, Spain (PO) (NCT02802267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top